What is the triple test and why does it require three components?

The triple test combines clinical examination (history and physical assessment by your GP), imaging (ultrasound if under 40, mammography plus ultrasound if 40 or over, or MRI for high-risk women), and tissue sampling (fine needle aspiration or core biopsy). A result is only considered reassuring when all three components independently agree the lump is benign — discordant results, where one raises concern while the others appear normal, require specialist surgical referral. This multi-component approach detects breast cancer with sensitivity approaching 99.6% and is the standard of care in Australia.

What does BreastScreen Australia cover and who can access it?

BreastScreen Australia provides free biennial screening mammography. The target group is women aged 50–74, who receive an automatic recall every two years. However, women from age 40 can self-refer by calling 13 20 50 — no GP referral is needed. Screening is for asymptomatic women only; if you have a new lump, nipple discharge, or skin change, you need a separate diagnostic referral to a radiologist for diagnostic imaging, not BreastScreen. Aboriginal and Torres Strait Islander women are encouraged to attend, with mobile services reaching remote areas.

What does my BI-RADS radiology result mean?

BI-RADS is the standardised classification radiologists use to communicate their findings. BI-RADS 1 and 2 are negative or benign — routine recall. BI-RADS 3 means probably benign, with less than a 2% chance of cancer — short-interval follow-up imaging at six months. BI-RADS 4 means suspicious and requires biopsy; BI-RADS 5 means highly suspicious and requires biopsy with urgent surgical referral. BI-RADS 0 means additional imaging is needed. Your GP or specialist will explain what your specific result means for management.

When should I be referred for genetic counselling about hereditary breast cancer?

Referral to a publicly funded family cancer service is appropriate when breast cancer was diagnosed under 45; cancer is triple-negative under 60; bilateral breast cancer occurred, especially if the first was under 50; a family member has a known pathogenic variant (BRCA1, BRCA2, PALB2, or others); breast and ovarian cancer appear on the same side of the family; or three or more relatives on the same side have breast, ovarian, pancreatic, or prostate cancer. Family cancer services are publicly funded in each Australian state and territory and accept GP referrals.

What are the evidence-based ways to reduce breast cancer risk?

The evidence most clearly supports: regular aerobic exercise of at least 150 minutes per week, which reduces risk by 10–25%; maintaining a healthy body weight, especially after menopause where adipose tissue increases circulating oestrogen through aromatase activity; limiting alcohol intake to no more than ten standard drinks per week, ideally fewer, with a linear dose-response from even one drink daily per the NHMRC 2020 alcohol guideline; and breastfeeding for twelve months total, which reduces risk by approximately 4%. These are lifestyle choices, not guarantees, and are best discussed with your GP in the context of your individual history.

Breast lump assessment and breast cancer screening

Breast lump assessment and screening: the Australian GP guide

By Dr HB Lo, FACRRM Reviewed 14 June 2026 11 min read

Breast lump assessment in Australian general practice uses the triple test — clinical examination, imaging, and tissue sampling — performed together. A result is reassuring only when all three components are concordantly normal; any discordant result requires specialist surgical referral.

BreastScreen Australia offers free biennial screening mammography to women aged 50–74, with self-referral from age 40. Women under 40 start with ultrasound; those aged 40 and over receive mammography plus ultrasound. Any persistent breast lump warrants investigation regardless of age or recent normal screening.

Breast cancer is the most commonly diagnosed cancer in Australian women, with approximately 20,640 new diagnoses each year. Lifetime risk is around 1 in 7 by age 85. Five-year survival has improved to approximately 92%, driven largely by earlier detection — which is why how GPs assess breast symptoms matters.

Most breast lumps presenting in general practice are benign. The challenge is reliably identifying the small proportion that are not. The triple test — clinical examination plus imaging plus tissue pathology — achieves sensitivity approaching 99.6% when all three components agree. When they do not agree, specialist referral is mandatory.

Equally important is understanding the population-level screening program. BreastScreen Australia targets asymptomatic women aged 50–74 with biennial mammography, but screening and diagnostic assessment are separate pathways. Symptomatic women should never be redirected to BreastScreen instead of receiving diagnostic imaging.

This article follows Cancer Australia guidance on investigation of new breast symptoms and the RACGP Red Book on preventive activities.

A. Core clinical — the AU general practice framework

Assessment principles

Any new breast symptom warrants triple testing regardless of age. Reassurance without completing the triple test is not safe practice and is the most common cause of breast cancer litigation in Australia (failure to investigate a persistent lump). The triple test sequence is:

Clinical examination — history and systematic breast examination
Imaging — age-appropriate imaging modality
Tissue sampling — FNA or core biopsy if indicated by BI-RADS result or clinical suspicion

A triple test is only considered negative when all three components are concordantly reassuring. Any discordant result — where one component raises concern while others appear benign — requires specialist surgical referral.

Clinical history

Key history elements:

Duration of lump; change over menstrual cycles
Pain — cyclical (usually benign) versus constant (requires assessment)
Nipple discharge — spontaneous, unilateral, single-duct, blood-stained, or associated mass raises concern
Skin changes — dimpling, peau d’orange, erythema, eczema of the nipple
Nipple changes — new inversion or deviation
Family history — three-generation pedigree (maternal and paternal)
Prior breast biopsies or imaging
Reproductive history — parity, breastfeeding, menarche, menopause age
Current medications — hormone replacement therapy, combined oral contraceptive pill
Alcohol intake, exercise, weight

Clinical examination

Systematic four-quadrant examination plus axilla and supraclavicular region. Best performed mid-cycle (days 7–10) in premenopausal women. Document size (millimetres), site (clock-face position and distance from areola), consistency, borders (discrete vs ill-defined), mobility, tethering to skin or deep tissue, and overlying skin changes.

Inspection: both arms relaxed, then raised, then hands on hips pressing inward. Palpation: vertical strips technique with the flat of the fingers; bilateral comparison.

Imaging by age

Under 40: ultrasound first — denser breast tissue reduces mammographic sensitivity; no radiation. Distinguishes cystic from solid. Targeted to the symptomatic area.

Age 40 and over: mammography (two views per breast — craniocaudal plus mediolateral oblique) plus adjunct ultrasound to the symptomatic area. Mammographic sensitivity declines in dense breasts (approximately 70% in dense versus 90% in fatty breast tissue).

MRI breast is indicated for:

BRCA1/2 mutation carriers (annual MRI from age 30, alongside annual mammography from age 40)
Lifetime risk over 25% per CanRisk/BOADICEA modelling
Prior chest radiotherapy under age 30 (Hodgkin survivors)
TP53 (Li-Fraumeni), CDH1, or PTEN pathogenic variants
Diagnostic problem-solving in equivocal cases

MBS items 63464/63467 apply when eviQ criteria are met; the private cost is approximately AUD 600–800 if criteria are not met.

BI-RADS classification

Radiologists report using BI-RADS (Breast Imaging Reporting and Data System):

BI-RADS	Interpretation	Management
0	Incomplete — needs further imaging	Additional imaging
1	Negative	Routine biennial recall
2	Benign finding	Routine recall
3	Probably benign (<2% malignancy risk)	Short-interval 6-month follow-up imaging
4A	Low suspicion (2–10%)	Core biopsy
4B	Moderate suspicion (10–50%)	Core biopsy
4C	High suspicion (50–95%)	Core biopsy and surgical referral
5	Highly suggestive of malignancy (>95%)	Core biopsy and urgent surgical referral
6	Known biopsy-proven malignancy	Treatment planning

Tissue sampling

Fine needle aspiration (FNA): cytological assessment; quick; best for cyst drainage (diagnostic and therapeutic) and palpable lumps with high pre-test probability of benign disease. Cannot reliably distinguish invasive from in-situ carcinoma. MBS item 30075.

Core biopsy: 14-gauge automated or vacuum-assisted biopsy; image-guided (ultrasound for most solid lesions, stereotactic for microcalcifications). Provides histology, grade, ER/PR/HER2 status, and Ki-67. Gold standard for diagnosing invasive breast cancer. MBS item 30078.

Excisional biopsy: reserved for discordant triple test where core biopsy is non-diagnostic, or for high-risk lesions (atypical ductal hyperplasia, papillary lesions, radial scar) that require excision to exclude underlying carcinoma.

BreastScreen Australia

BreastScreen Australia provides free biennial screening mammography. Key points for GPs:

Target group 50–74: automatically recalled every two years
Self-referral from age 40: call 13 20 50 (no GP letter required)
Symptomatic women should NOT use BreastScreen — refer for diagnostic imaging instead
ATSI women: culturally safe access through mobile units and Indigenous Health Workers
Trans and non-binary individuals with breast tissue are welcomed; individual discussion about eligibility
CALD women: interpreters via TIS National 131 450
Recall rate approximately 6%; cancer detection approximately 6 per 1,000 screens first round

B. Evidence appraisal

Population screening: benefit and limitation

Multiple randomised trials collectively show biennial mammographic screening in women 50–74 reduces breast cancer mortality by approximately 20% relative to no screening. Absolute benefit is modest in the early 50s and larger in the mid-60s. False-positive rates — approximately 6% recall, of which most turn out to be benign — cause short-term anxiety and additional investigations.

Mammographic screening in women aged 40–49 is more complex: modestly effective but with a higher false-positive rate and greater risk of overdiagnosis of ductal carcinoma in situ that may never progress to clinically significant cancer. BreastScreen allows self-referral from age 40 but does not actively recall this group.

MRI in high-risk women

Three landmark trials (MARIBS UK, DOM Dutch, Kuhl German) consistently show MRI sensitivity of 71–94% in BRCA1/2 carriers and other high-risk women, compared to 33–59% for mammography alone in the same young high-risk group. Annual MRI from age 30 plus mammography from age 40 is the evidence-based standard for BRCA1/2 carriers.

Chemoprevention

NSABP P-1 (tamoxifen) and IBIS-I showed tamoxifen 20 mg daily for five years reduces invasive oestrogen receptor-positive breast cancer by approximately 49% in high-risk women. Benefit persists for 20 or more years. Tamoxifen is PBS-listed with Authority Required for treatment and for risk-reduction in documented high-risk individuals.

IBIS-II showed anastrozole reduces breast cancer risk by 53% over five years in postmenopausal high-risk women, but anastrozole is not PBS-listed for chemoprevention (off-label, private prescription approximately AUD 30/month).

Against routine self-breast-examination

The Shanghai and Russian randomised trials (>260,000 women) showed no breast cancer mortality benefit from monthly taught self-breast-examination, but a significant increase in benign biopsy rates. The RACGP Red Book instead promotes breast awareness — familiarity with how one’s own breasts normally look and feel — rather than a formal monthly examination protocol.

C. Hereditary breast cancer

Indications for family cancer service referral

Refer to the publicly funded family cancer service in your state when any of the following apply:

Breast cancer diagnosed under 45 (especially under 40)
Triple-negative breast cancer diagnosed under 60
Bilateral breast cancer (especially first diagnosis under 50)
Breast cancer plus ovarian cancer in the same individual or in close relatives on the same side
Male breast cancer in any relative
Ashkenazi Jewish heritage with breast or ovarian cancer
Three or more relatives with breast, ovarian, pancreatic, or prostate cancer on the same side of the family
Known pathogenic variant in the family
CanRisk/BOADICEA modelling showing lifetime risk over 30%

High-penetrance genes and surveillance

Gene	Breast lifetime risk	Key management
BRCA1	60–72%	Annual MRI from 30; mammography from 40; consider risk-reducing salpingo-oophorectomy age 35–40
BRCA2	55–69%	Annual MRI from 30; mammography from 40; consider RRSO age 40–45
PALB2	35–58%	Annual MRI from 30
CHEK2/ATM	20–30%	Annual mammography from 40
TP53 (Li-Fraumeni)	Up to 85%	Annual MRI from age 20; avoid mammography in youth
CDH1	39–52% (lobular)	Annual MRI from 30; plus gastric surveillance

PBS-funded genetic testing (MBS items 73297/73299) requires documented criteria; specialist genetics service typically requests. eviQ provides the Australian clinical pathways for genetic risk management.

Risk-reducing options

Confirmed high-risk women (BRCA1/2, PALB2) may consider:

Enhanced surveillance — ongoing MRI plus mammography per gene-specific protocol
Chemoprevention — tamoxifen (premenopausal or postmenopausal ER+ risk reduction), anastrozole (postmenopausal)
Risk-reducing mastectomy — reduces breast cancer risk by approximately 95%; irreversible; requires multidisciplinary team discussion
Risk-reducing salpingo-oophorectomy — reduces ovarian cancer risk and (in premenopausal women) reduces breast cancer risk; triggers surgical menopause; discuss HRT in absence of personal breast cancer

D. Australian operations

Key MBS items

Item	Description
23	Level B consultation — initial symptom assessment
36	Level C — full triple-test history and imaging request
44	Level D — hereditary risk counselling, preparation for family cancer service
132/133	Complex chronic disease management plan (post-cancer surveillance)
715	Aboriginal and Torres Strait Islander health assessment
707	75+ health assessment (screening review included)
2715/2717	Mental Health Treatment Plan (BRCA-positive distress, fear of recurrence)
59300/59303	Diagnostic mammography (unilateral / bilateral)
55070/55076	Breast ultrasound (one or both breasts)
63464/63467	Breast MRI — high-risk only; eviQ criteria required
30075	Fine needle aspiration
30078	Core biopsy
73297/73299	BRCA1/2 genetic testing
73296	Cascade testing for known familial variant

PBS authority

Tamoxifen 20 mg daily — Authority Required; PBS for ER+ breast cancer treatment; risk-reduction Authority in documented high-risk
Anastrozole — Authority Required for postmenopausal HR+ breast cancer treatment; off-label for chemoprevention
Olaparib (Lynparza) — PBS Authority for BRCA1/2-mutated metastatic and high-risk early breast cancer; oncologist initiated

Referral pathways

Breast surgical clinic — any BI-RADS 4–5, discordant triple test, persistent unresolved lump
Public breast clinics — tertiary hospital clinics; typically 2–4 weeks urgent
Private breast surgeon — typically under 2 weeks
Family cancer services — Peter MacCallum (VIC), Prince of Wales (NSW), Royal Brisbane (QLD), Women’s and Children’s (SA), KEMH (WA), and equivalents nationally; GP referral letter required
McGrath Breast Care Nurses — funded by McGrath Foundation; coordinate care during diagnosis and treatment

Cultural safety

ATSI women — approach via Aboriginal Community Controlled Health Services where possible; use 715 assessment as gateway; female clinician or chaperone on request; community navigation support
CALD women — TIS National interpreter service (131 450) mandatory if English not fluent; written information from Health Translations Victoria
Trans and gender-diverse patients — affirming language; assessment of chest wall tissue appropriate to anatomy

E. Special populations

Women under 40: ultrasound first for any discrete lump. Mammography can be added if ultrasound identifies a suspicious solid lesion. MRI for BRCA or other high-penetrance gene carriers per protocol. Reassurance without imaging is not appropriate for a new discrete lump in any age group.

Pregnancy and lactation: ultrasound first; mammography with abdominal shielding is safe if needed (gestational radiation dose approximately 0.4 mGy). Pregnancy-associated breast cancer (occurring within one year of delivery) is a clinical entity with a generally worse prognosis because presentation is often delayed. Any persistent lump in a pregnant or recently postpartum woman warrants investigation.

Breast implants: ultrasound and MRI are the primary imaging modalities; mammography uses special Eklund compression views. Consider BIA-ALCL (anaplastic large cell lymphoma in the implant capsule) in women with late-onset seroma or unexplained implant swelling — refer to a breast surgeon.

Male breast lump: the triple test applies equally. Gynaecomastia is common (especially in older men, and with medications including spironolactone, antiandrogens, and oestrogens), but unilateral, eccentric, hard, or adherent lumps warrant imaging and biopsy. Male breast cancer accounts for approximately 1% of all breast cancers.

When to escalate

Any discordant triple test — immediate specialist surgical referral, regardless of which component is discordant
BI-RADS 4 or 5 — core biopsy plus surgical referral; do not reassure and wait
Inflammatory breast cancer signs — peau d’orange, rapid onset, diffuse erythema — urgent (same-week) specialist review; inflammatory breast cancer can mimic mastitis
Paget’s disease of the nipple — eczematoid nipple changes — biopsy mandatory
Axillary mass with no identified breast primary — specialist referral (occult primary)
New nipple inversion or skin tethering in a postmenopausal woman — urgent referral
Known BRCA carrier with new lump — same pathway; enhanced vigilance does not lower the threshold for investigation

What this article is and is not

This is general health information drawn from Cancer Australia guidelines, the RACGP Red Book, NHMRC familial breast cancer guidelines, and eviQ cancer genetics pathways. It is not personal medical advice and does not create a doctor–patient relationship. Any new breast lump or change should be assessed by your GP.

For consumer-friendly information: BreastScreen Australia 13 20 50, Breast Cancer Network Australia (BCNA), Pink Hope, HealthDirect — Breast lumps.

Sources cited

Frequently asked questions

What is the triple test and why does it require three components?

The triple test combines clinical examination (history and physical assessment by your GP), imaging (ultrasound if under 40, mammography plus ultrasound if 40 or over, or MRI for high-risk women), and tissue sampling (fine needle aspiration or core biopsy). A result is only considered reassuring when all three components independently agree the lump is benign — discordant results, where one raises concern while the others appear normal, require specialist surgical referral. This multi-component approach detects breast cancer with sensitivity approaching 99.6% and is the standard of care in Australia.
What does BreastScreen Australia cover and who can access it?

BreastScreen Australia provides free biennial screening mammography. The target group is women aged 50–74, who receive an automatic recall every two years. However, women from age 40 can self-refer by calling 13 20 50 — no GP referral is needed. Screening is for asymptomatic women only; if you have a new lump, nipple discharge, or skin change, you need a separate diagnostic referral to a radiologist for diagnostic imaging, not BreastScreen. Aboriginal and Torres Strait Islander women are encouraged to attend, with mobile services reaching remote areas.
What does my BI-RADS radiology result mean?

BI-RADS is the standardised classification radiologists use to communicate their findings. BI-RADS 1 and 2 are negative or benign — routine recall. BI-RADS 3 means probably benign, with less than a 2% chance of cancer — short-interval follow-up imaging at six months. BI-RADS 4 means suspicious and requires biopsy; BI-RADS 5 means highly suspicious and requires biopsy with urgent surgical referral. BI-RADS 0 means additional imaging is needed. Your GP or specialist will explain what your specific result means for management.
When should I be referred for genetic counselling about hereditary breast cancer?

Referral to a publicly funded family cancer service is appropriate when breast cancer was diagnosed under 45; cancer is triple-negative under 60; bilateral breast cancer occurred, especially if the first was under 50; a family member has a known pathogenic variant (BRCA1, BRCA2, PALB2, or others); breast and ovarian cancer appear on the same side of the family; or three or more relatives on the same side have breast, ovarian, pancreatic, or prostate cancer. Family cancer services are publicly funded in each Australian state and territory and accept GP referrals.
What are the evidence-based ways to reduce breast cancer risk?

The evidence most clearly supports: regular aerobic exercise of at least 150 minutes per week, which reduces risk by 10–25%; maintaining a healthy body weight, especially after menopause where adipose tissue increases circulating oestrogen through aromatase activity; limiting alcohol intake to no more than ten standard drinks per week, ideally fewer, with a linear dose-response from even one drink daily per the NHMRC 2020 alcohol guideline; and breastfeeding for twelve months total, which reduces risk by approximately 4%. These are lifestyle choices, not guarantees, and are best discussed with your GP in the context of your individual history.

Source quality

Sources grouped by evidence tier. AU primary tier first; international where AU is silent or lagging; named-author reconstruction where guidelines have not yet caught up. How tiers work.